Evaluating response to immunotherapy with ¹⁸F-FDG PET/CT: where do we stand?

Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021. doi: 10.1007/s00259-020-04702-4.

Authors

Nicolas Aide^{1

2

3}, Michel De Pontdeville⁴, Egesta Lopci⁵

Affiliations

¹ Nuclear Medicine Department, Centre Hospitalier Universitaire, Avenue Côte de Nacre, 14000, Caen, France. aide-n@chu-caen.fr.
² Normandie University, Caen, France. aide-n@chu-caen.fr.
³ INSERM ANTICIPE, Normandie University, Caen, France. aide-n@chu-caen.fr.
⁴ Dermatology Department, Centre Hospitalier Universitaire, Caen, France.
⁵ Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Rozzano, Italy.

PMID: 31996974
DOI: 10.1007/s00259-020-04702-4

No abstract available

Publication types

Editorial
Comment

MeSH terms

Fluorodeoxyglucose F18*
Humans
Immunotherapy
Lung Neoplasms*
Positron Emission Tomography Computed Tomography
Tumor Burden

Substances

Fluorodeoxyglucose F18